© 2026 CellCarta - All rights reserved.
THE CDx MODEL NEEDS TO CHANGE
Advancing Oncology Biomarker Strategies During ASCO 2026
Meet the CellCarta team in Boston to explore our fast, flexible paths from early biomarker work to a launch-ready companion diagnostic, with the options to move to a single site and kitted launch when you're ready.
WORLD CB & CDX 2026
THE CDx MODEL NEEDS TO CHANGE
October 6-8, 2026
FEATURED PRESENTATION · OCTOBER 7 · 12:10 PM
The CDx Model Needs to Change: What China taught us about breaking silos, moving faster, and going global.
Christopher Ung, Chief Scientific Business Officer at CellCarta, will share how an integrated CRO–manufacturer model replaces sequential handoffs with alignment, parallel execution, and joint governance, built to run at the speed of China's emerging biopharma industry.
After launching in China, we're showing how those principles can scale globally and continue to move therapeutics from innovation to impact in a complex CDx ecosystem.
Find the right CDx pathway for your therapeutic.
Book time with CellCarta’s team at World CB & CDx for expert advice on your roadmap, timelines, and commercialization options.
FEATURED PRESENTATION · OCTOBER 7 · 12:10 PM
The CDx Model Needs to Change: What China taught us about breaking silos, moving faster, and going global.
Christopher Ung, Chief Scientific Business Officer at CellCarta, will share how an integrated CRO–manufacturer model replaces sequential handoffs with alignment, parallel execution, and joint governance, built to run at the speed of China's emerging biopharma industry. After launching in China, we're showing how those principles can scale globally and continue to move therapeutics from innovation to impact in a complex CDx ecosystem.
Find the right CDx model for your therapeutic.
Boston, MA
WHY MEET CELLCARTA AT WORLD CB & CDX
Build for the CDx you need now - and the one you might need next.
Build for the CDx you need now - and the one you might need next.
WHY MEET CELLCARTA AT WORLD CB & CDX
01
Preserve optionality early
A flexible, modular approach lets you begin with lower risk and investment while keeping a clear path toward CDx development and commercialization.
02
Prepare for accelerated timelines
When breakthrough designation or an accelerated approval changes the plan, build toward a diagnostic that can keep pace with the therapeutic timeline.
03
Scale without a costly handoff
Align development, validation, regulatory planning, and deployment around one global model designed to reduce transfer risk through our collaborative CDx Lab Network.
DON'T LEAVE YOUR CDx PLAN TO CHANCE
OCTOBER 7-8
BOSTON, MA
DON'T LEAVE YOUR CDx PLAN TO CHANCE
Find the right CDx model for your therapeutic.
Book time with CellCarta’s team at World CB & CDx for expert advice on your roadmap, timelines, and commercialization options.
October 7-8, 2026
Boston, MA
01
A flexible, modular approach lets you begin with lower risk and investment while keeping a clear path toward CDx development and commercialization.
Preserve optionality early
02
Prepare for accelerated timelines
A flexible, modular approach lets you begin with lower risk and investment while keeping a clear path toward CDx development and commercialization.
03
Align development, validation, regulatory planning, and deployment around one global model designed to reduce transfer risk through our collaborative CDx Lab Network.
Scale without a costly handoff
The CDx Model Needs to Change: What China taught us about breaking silos, moving faster, and going global.
Book time with CellCarta’s team at World CB & CDx for expert advice on your roadmap, timelines, and commercialization options. .
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner.
Our Global Footprint
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Connect with our team to explore how our owned laboratories across North America, Europe, Australia, and China can deliver globally consistent execution from a single, integrated partner.
